Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
261 people get ENZN articles and Market Currents by email alert.
Get email alerts on ENZN »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
Marketwire (Mar 18, 2013)
-
-
-
-
-
-
Marketwire (Dec 17, 2012)
-
Marketwire (Nov 29, 2012)
-
Tracking Seth Klarman's Baupost Group Holdings - Q3 2012 UpdateJohn Vincent • Wed, Nov 14, 2012
-
Marketwire (Nov 8, 2012)
-
Marketwire (Oct 31, 2012)
-
Marketwire (Sep 11, 2012)
-
-
-
Marketwire (Aug 1, 2012)
To learn more about Seeking Alpha Pro, click here.
-
-
Anything Positive At Enzon?Suman Chatterjee • Sun, Sep 25, 2011 -
Enzon Pharmaceuticals: A Two-Platform CompanyJason Chew • Tue, Dec 21, 2010 -
-
-
Enzon Shareholders Demand ChangeEben Tessari • Wed, May 21, 2008 -
-
-
Carl Icahn Boosts Stake in Enzon PharmLon Juricic • Mon, Mar 17, 2008
-
-
-
-
-
-
-
-
-
-
Tracking Seth Klarman's Baupost Group Holdings - Q3 2012 UpdateJohn Vincent • Wed, Nov 14, 2012
-
-
-
-
-
-
4 Highly Liquid Biotech Stocks With Bullish Short TrendsKapitall • Thu, May 10, 2012 -
-
-
-
-
-
Enzon Pharmaceuticals, Inc. Q1 2010 Earnings Call TranscriptMon, May 10, 2010
-
Enzon Pharmaceuticals, Inc. Q2 2008 Earnings Call TranscriptMon, Aug 11, 2008
-
Enzon Pharmaceuticals Inc., Q1 2008 Earnings Call TranscriptWed, May 7, 2008
-
Marketwire (Mar 18, 2013)
-
at CNBC.com (Dec 17, 2012)
-
at CNBC.com (Dec 17, 2012)
-
at CNBC.com (Dec 17, 2012)
-
Marketwire (Dec 17, 2012)
-
Marketwire (Nov 29, 2012)
-
Marketwire (Nov 8, 2012)
-
Marketwire (Oct 31, 2012)
-
Marketwire (Sep 11, 2012)
-
Marketwire (Aug 1, 2012)
-
Marketwire (May 2, 2012)
-
Marketwire (Mar 12, 2012)
-
at MarketWatch.com (Sep 23, 2011)
-
at CNBC.com (Aug 10, 2011)
ENZN vs. ETF Alternatives
Company Description
We are a biopharmaceutical company dedicated to developing, manufacturing and commercializing important medicines for patients with cancer and other life-threatening conditions. We have a portfolio of four marketed products, Oncaspar®, DepoCyt®, Abelcet® and Adagen®. Our drug development... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Wednesday, April 24, 11:27 AM Enzon Pharmaceuticals (ENZN -11.5%) flips an early pre-market gain to trade lower after the company unveiled a special dividend, a move that comes as the biopharmaceutical company concluded an earlier review of strategic alternatives and a workforce reduction. Late last year, Carl Icahn divulged a 13.3% stake in the company, and was taking an active interest in its operations and direction. Comment! [Healthcare, On the Move]
- Tuesday, April 23, 6:38 PM Enzon Pharmaceuticals (ENZN) declares special dividend of $1.60/share. For shareholders of record May 07. Payable June 04. Ex-div date May 03. (PR) 6 Comments [Dividends]
-
Tuesday, April 23, 5:48 PM
After-hours top gainers, as of 5:15 p.m.: IRBT +14%. ENZN +7%. YUM +6%. BRCM +5%. AAPL +5%.
After-hours top losers: VOCS -30%. UIS -16%. DV -12%. AWAY -8%. PNRA -6%. Comment! [On the Move] - Wednesday, March 27, 10:42 AM Enzon Pharmaceuticals (ENZN -2.8%) hits a new 52-week low after disclosing in a regulatory filing late yesterday that it's reducing its workforce from 19 employees to 12. It expects to incur about $1.3M in charges related to the reduction in force, due to cash expenditures for one-time employee termination benefits and associated costs. The company expects to record the charges and complete the reduction by the end of Q1. 1 Comment [Healthcare, On the Move]
- Tuesday, March 19, 6:39 AM Enzon Pharmaceuticals (ENZN): Q4 EPS of -$0.11. Revenue of $10.6M. (PR) Comment! [Earnings, Breaking News, Healthcare]
- Monday, December 17, 2012, 10:33 AM Shares of Enzon Pharmaceuticals (ENZN) have resumed trading following an earlier halt, and the shares are currently up 5.4%. Carl Icahn has a 13.29% stake in Enzon, and disclosed in November that he and his associates wanted to discuss the operations and direction of the company. Comment! [Healthcare, On the Move]
-
Monday, December 17, 2012, 9:10 AM
Premarket gainers: JVA +12%. ENZN +10%. CBMX +10%. LXRX +9%. TROX +6%. CTIC +5%.
Losers: NBG -13%. CLWR -11%. SQNM -6%. Comment! [On the Move] - Monday, December 17, 2012, 7:28 AM Enzon Pharmaceuticals (ENZN) halts clinical development and has hired Lazard to explore a sale of the company. The move comes about 2 weeks after Carl Icahn renewed his push for a change in direction. Shares halted. (PR) Comment! [Healthcare]
-
Thursday, December 6, 2012, 12:45 PM
Midday top 10 gainers: BSDM +28%. EPHC +27%. MBLX +22%. INPH +18%. NVGN +18%. UEPS +17%. HITK +13%. CZR +11%. MITK +11%. CVO +11%.
Midday top 10 Losers: ENZN -30%. TIGR -19%. SCMR -17%. NBY -16%. LFVN -14%. WEBM -14%. SNFCA -13%. KBW -13%. VRA -12%. HF -11%. Comment! [On the Move] -
Thursday, December 6, 2012, 9:10 AM
Premarket gainers: WLT +7%. ZNGA +6%. AKAM +5%.
Losers: ENZN -28%. VRA -10%. MW -10%. COST -7%. ERJ -6%. LFVN -6%. LVS -5%.
Comment! [On the Move] - Thursday, November 29, 2012, 5:34 PM Enzon Pharmaceuticals (ENZN) declares special dividend of $2.00/share. For shareholders of record Dec 10. Payable Dec 21. Ex-div date Dec 06. (PR) Comment! [Dividends]
- Wednesday, November 28, 2012, 3:29 PM Enzon Pharmaceuticals (ENZN -0.6%) slip after activist investor Carl Icahn files an amended 13D requesting a discussion on the company's operations and direction, as well as the it's plans to preserve shareholder value. Comment! [Healthcare]
- Tuesday, February 28, 2012, 5:42 PM Enzon Pharmaceuticals (ENZN) discloses it has appointed Icahn Capital's George Hebard to a new board seat. Carl Icahn has long pushed for a management overhaul at Enzon. Comment! [Healthcare]
-
Thursday, December 16, 2010, 9:00 AM
Premarket gainers: CUR +11%. CCME +9%. UEC +7%. VG +7%. ENZN +7%. NVAX +6%. ERIC +4%. ARO +4%. MORT +4%. PCBC +4%. MCP +4%.
Losers: RGS -8%. Comment! - Monday, November 9, 2009, 8:33 AM Enzon Pharmaceuticals (ENZN) to sell its specialty pharmaceutical business to the sigma-tau Group for $300M plus another $27M if it hits certain milestones. ENZN will also retain royalties of 5-10%on incremental net sales above a baseline amount. ENZN is halted. Comment!
- Thursday, October 22, 2009, 1:56 PM Why aren't you blogging, Carl Icahn? "I've been sort of busy. And right now, with the market up, there's not as much interest in corporate governance like there was a couple of months ago." Damien Park notes Carl's been among the most active of activists, seeking board seats at Enzon Pharmaceuticals (ENZN), Biogen (BIIB), Amylin (AMLN) and Lions Gate (LGF), and contuining to pester Yahoo (YHOO). 1 Comment
-
MagicDiligence
Also new to the Magic Formula is Enzon Pharma $ENZN. Y! profile starts: "Enzon Pharmaceuticals, Inc. does not have significant operations." - View all 0 replies
-
- View all 3 replies
-
Ocean Man: Maybe, or you could go long ENZN and short MHH. But nothing's a sure thing.
-
-
Jim Van Meerten
ENZN - 60% Barchart technical sell signal - lost 7.90% in the last month - Relative Strength Index 34.59% - View all 0 replies
-
Jim Van Meerten
ENZN - 32% Barchart technical buy signal - 10 new hgihs and up 14.42% in the last month - Relative Strength Index 66.05% - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
- View all 3 replies
-
Ocean Man: Maybe, or you could go long ENZN and short MHH. But nothing's a sure thing.
-